Welcome to Browse Page of Biomarker

This page shows the result of browsing biomarker from different fieldss.For more information see HELP page.

The total number entries retrieved from this search are 5
Please click on Biomarker_ID to view detailed information.
Note: Potential Biomarker with * indicates these signatures are candidate biomarkers extracted from experiments on mice, rat or cell lines and they are not validated on human patients'cohort.
Biomarker IDBiomarkerBiomoleculeSubjectRegulationBiomarker's typeExperimentLevel of significanceSourcePMID
2461FAM34A, NARS, HSPC152, GRP58, GBA, PVRL2, RPS17, LAMR1, GNB1, AHNAK, GRCC10, SPTAN1, CTSC, NSE1, COP1, NDRG1, HSPA5, SPARC, ATP5J2, KIAA0663, CD24, NUDT3, CANXRNAsHumanDownregulated in among all types HCC v/s non-tumor DiagnosticHCC v/s non-tumor p < 0.01Tissue16391793
2503Fibronectin, Tubulin-alpha-1 subunit, Matrix metalloproteinase 14, osteonectin SPARC, RAD23A, Ubiquitin-conjugating enzyme E2, Neutrophil-gelatinase associated lipocalin precursor lipocalin 2, TRAM protein, ADP/ATP carrier protein, High mobility group protein, Insulin stimulated protein kinase 1, TrRNAsHumanDiffrenetially expressed in HCC v/s non-tumor DiagnosticHCC v/s non-tumor p < 0.01Tissue11973655
2543TACSTD1, MYH4, PSPHL, CXCR4, N33, GMNN, MGP, RGS2, G1P2, AREG, EMP1, IFIT1, SPINK1, ADAMTS1, SLC2A3, EPHA3, GJA1, RDC1, KCNJ16, MX1, KRT23, THBD, MTHFD2, IFI44, IGF1, SGCE, SPARCL1, CYP3A5, ATP8B1RNAsHumanDownregulated in late cirrhosis than early cirrhosis (with more than 3 fold) PrognosticEarly v/s Late HCV Cirrhosis p < 0.05Tissue15108252
2547FBN1, MEF2C, TNFAIP3, LAPTM5, TMSB4X, CUGBP2, HLA-DRA, REL, clone110298, LTBP2, TRIM22, HLA-DRBI, FOXF1, HLA-DQA, SDF1, DDX17, SGK, PDGFRA, F2R, HLADG, MTAP44, CTSK, VIM, ACVR1, ON/SPARC, SCYA3, ARHGEF6, CCND2, COL1A1, ITGB2/CD18, PTPRC, MKNK1, JUNB, EST, GATA6, FUT3, RDBP, E48, SEMA3F, COL6A3, GBAPRNAsHuman 11 genes (FUT3, RDBP, E48, SEMA3F, COL6A3, GBAP, FUT1, GCHFR, CYP2A, MLH1, EST) Upregulated and rest 35 genes downregulated in HCC with early IHR vs. HCC without recurrence PrognosticIntrahepatic recurrence v/s Non-recurrence p < 0.05Tissue15688398
2566Matrixmetalloproteinase14 or MMP14, MT-MMP1,osteonectin/SPARCRNAsHumanUpregulated in all three tested HCC samples. Diagnostic HCC v/s non-tumor p < 0.05Tissue11813304

         Raghava's group    CancerCSP    CancerSPP    CancerPDF    CancerTSP    CancerLSP    HCCPred   

Scroll to Top